Regulation - Chelsea Therapeutics

Filter

Current filters:

Chelsea Therapeutics

Popular Filters

Surprise FDA advisory panel backing for Chelsea’s Northera

Surprise FDA advisory panel backing for Chelsea’s Northera

15-01-2014

A US Food and Drug Administration advisory panel has voted 16-one to recommend approval of US biotech…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRegulationUSA

US FDA further delays Chelsea's Northera

29-07-2013

US biotech firm Chelsea Therapeutics (Nasdaq: CHTP) has received acknowledgment of its resubmitted New…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRegulation

Chelsea Therapeutics resubmits NDA for Northera to the US FDA

10-07-2013

US biotech firm Chelsea Therapeutics (Nasdaq: CHTP) has resubmitted a New Drug Application to the US…

Cardio-vascularChelsea TherapeuticsNortheraPharmaceuticalRegulation

Chelsea Thera to re-file Northera NDA with existing data; Celgene share buyback

21-02-2013

Chelsea Therapeutics International (Nasdaq: CHTP) saw its shares more than double to $1.61 in pre-market…

BiotechnologyCardio-vascularCelgeneChelsea TherapeuticsFinancialNorth AmericaNortheraRegulation

Chelsea Thera gets disappointing news from FDA on Northera

04-07-2012

US biotech firm Chelsea Therapeutics International (Nasdaq: CHTP) shares tumbled in pre-market trading…

BiotechnologyCardio-vascularChelsea TherapeuticsNorth AmericaNortheraRare diseasesRegulation

FDA calls for more data from Chelsea Thera on Northera

30-03-2012

The US Food and Drug Administration has issued a complete response letter regarding the New Drug Application…

BiotechnologyChelsea TherapeuticsNeurologicalNorth AmericaNortheraRegulation

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top